Analysts say Roche's potential is underestimated

Over the current book year the total revenue will be 53,46 billion CHF (consensus estimates). This is slightly more than 2016's revenue of 50,58 billion CHF.

Historical revenues and results Roche plus estimates 2018

The analysts expect for 2018 a net profit of 13,15 billion CHF. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 15,5 CHF. The PE-ratio therefore is 15,05.

Huge dividend Roche

Per share the analysts expect a dividend of 8,59 CHF per share. Roche 's dividend yield thus equals 3,68 percent. The average dividend yield of the pharmaceutical companies equals a low 0,42 percent.

Most recent target prices around 291 CHF

The most recent recommendations for the pharmaceutical company are from Barclays , Independent Research and Liberum.

Based on the current number of outstanding shares Roche 's market capitalization 161,38 billion CHF.

Historical stock prices Roche

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.